MintNeuro

MintNeuro is an Imperial College London spin-out developing next-generation semiconductor technology for neural implants. Founded in 2022 by Dr Dorian Haci and Professor Tim Constandinou, the company is addressing a fundamental problem in the neurology field: existing neural implants are too large, too power-hungry, and too expensive to manufacture, limiting their accessibility and clinical utility. MintNeuro is building the semiconductor chips that will power a new generation of minimally invasive, cost-effective implantable devices for treating neurological conditions.

The company's modular chip architecture integrates sensing, stimulation, signal processing, power management, and wireless communication into devices that can be up to 1,000 times smaller than current implant technologies. These chips are designed to be plug-and-play for medical device companies, allowing innovators to focus on patient outcomes rather than chip design. MintNeuro has active collaborations with NHS partners through the NIHR-funded DREAM epilepsy monitoring project, and with Amber Therapeutics through the Innovate UK-funded GOLD project to develop a neuromodulation therapy chip for urinary incontinence and other conditions.

MintNeuro has received over £14 million in underpinning R&D grant funding and raised over £2 million in equity investment from Empirical Ventures, Parkwalk Advisors, Imperial College London, Plug & Play, and ARIA. In 2025, the company won three UK Government ARIA awards, was named ChipStart Company of the Year, and was selected for the Microsoft and NVIDIA Agentic Launchpad programme.